Last Updated: July 14, 2026

Litigation Details for Plaintiff(s) v. Defendant(s) (D. Del. 2016)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Plaintiff(s) v. Defendant(s)
The small molecule drugs covered by the patents cited in this case are ⤷  Start Trial and ⤷  Start Trial .

Details for Plaintiff(s) v. Defendant(s) (D. Del. 2016)

Date Filed Document No. Description Snippet Link To Document
2016-01-01 External link to document
2015-12-31 638 Exhibit I - US Patent 7,601,758, # 10 Exhibit J - US Patent 7,820,681, # 11 Exhibit K - US Patent 7,915,269…Exhibit C - US Patent 7,906,519, # 4 Exhibit D - US Patent 7,935,731, # 5 Exhibit E - US Patent 8,093,298,…Exhibit F - US Patent 7,964,648, # 7 Exhibit G - US Patent 8,093,297, # 8 Exhibit H - US Patent 7,619,004,…Exhibit L - US Patent 7,964,647, # 13 Exhibit M - US Patent 7,981,938, # 14 Exhibit N - US Patent 8,093,296…Exhibit O - US Patent 8,097,655, # 16 Exhibit P - US Patent 8,415,395, # 17 Exhibit Q - US Patent 8,415,396 External link to document
2015-12-31 9 1860134. (Attachments: # 1 Exhibit A - U.S. Patent No. 7,608,282, # 2 Civil Cover Sheet)(Bellew, Joseph) External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Litigation Summary and Analysis for Plaintiff(s) v. Defendant(s) in 1:99-mc-02016

Last updated: July 8, 2026

What does 1:99-mc-02016 cover, and why is it in litigation dockets?

This filing is docketed as 1:99-mc-02016, where “mc” denotes a miscellaneous case category used by federal courts for procedural or administrative matters that are not a standard civil action. The case number format indicates a 1999 initiation year.

No party names, claims, court, presiding judge, filings, or outcomes are provided with the docket identifier in the prompt. Without those details, a complete and accurate plaintiff-versus-defendant litigation narrative cannot be constructed to support business, licensing, litigation, or regulatory decisions.

Who are the plaintiffs and defendants in 1:99-mc-02016?

No plaintiff or defendant identities are supplied for 1:99-mc-02016, so the case caption cannot be reconstructed.

What filings, motions, and procedural steps occurred in 1:99-mc-02016?

The prompt provides no docket events (complaint, answer, motion to dismiss, transfer, consolidation, discovery order, settlement, or dismissal) tied to 1:99-mc-02016. Without docket text or event dates, a procedural timeline cannot be produced.

What is the status or outcome of 1:99-mc-02016?

No disposition data (dismissal with prejudice, without prejudice, settlement, remand, or final judgment) is provided. A legal outcome assessment cannot be stated.

How strong is the litigation posture for plaintiffs vs. defendants in 1:99-mc-02016?

Without:

  • asserted causes of action,
  • defenses,
  • jurisdiction and venue,
  • relevant patent/regulatory context (if any),
  • and any court reasoning, no litigation-strength analysis can be generated without becoming speculative.

What settlements, consent judgments, or licensing outcomes followed from 1:99-mc-02016?

No settlement or consent terms are provided. No licensing impact can be derived.

What patent or FDA regulatory impacts connect to 1:99-mc-02016?

The prompt provides no linkage between 1:99-mc-02016 and:

  • Orange Book patents,
  • Paragraph IV litigation,
  • Hatch-Waxman settlements,
  • biosimilar exclusivity,
  • or FDA approvals.

What generic entry risks were implicated by 1:99-mc-02016?

No drug, patent, OR FDA reference listed drug, or regulatory pathway is provided. Generic entry risk analysis cannot be tied to the docket.

How does 1:99-mc-02016 compare with other similar “mc” dockets?

No additional docket comparators are provided (e.g., related actions, consolidation orders, or companion cases). Comparative analysis cannot be performed.

Key Takeaways

  • 1:99-mc-02016 is a miscellaneous federal court docket initiated in 1999, but the prompt includes no caption, claims, events, or disposition details.
  • A litigation summary and plaintiff-versus-defendant analysis cannot be completed accurately from the docket identifier alone.

FAQs

  1. What court handles “mc” dockets like 1:99-mc-02016?
  2. Do “miscellaneous cases” typically involve patent disputes or procedural issues?
  3. How can 1:99-mc-02016 relate to Hatch-Waxman litigation outcomes?
  4. What information is needed to extract a true timeline from a federal docket number?
  5. How do docket dispositions affect downstream licensing or FDA approvals?

References

No sources were cited because no docket content, court, parties, events, or disposition details were provided in the prompt.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.